Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn. Pharmaceuticals Inc.filedCriticalIcn. Pharmaceuticals Inc.
Priority to YU43500ApriorityCriticalpatent/YU43500A/en
Publication of YU43500ApublicationCriticalpatent/YU43500A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Objavljuju se nova jedinjenja purin L-nukleozida, kod kojih su i prsteni purina i šećer bili modifikovani, ili oba. Nova jedinjenja ili njihovi farmaceutski prihvatljivi estri ili soli mogu se koristiti u farmaceutskim preparatima, i takvi preparati se mogu upotrebljavati za tretman infekcija, zaraza, neoplazmi, ili autoimunih oboljenja. Nova jedinjenja se takodje mogu koristiti i za modulisanje vidova imunosistema, uključujući modulaciju Th1 i Th2.New purine L-nucleoside compounds are published, in which both the purine and sugar rings have been modified, or both. New compounds or their pharmaceutically acceptable esters or salts may be used in pharmaceutical preparations, and such preparations may be used to treat infections, infections, neoplasms, or autoimmune diseases. The new compounds can also be used to modulate aspects of the immune system, including modulation of Th1 and Th2.
YU43500A2000-07-102000-07-10Purine-l-nucleosides, analogs and uses thereof
YU43500A
(en)